• PP2A, Autophagy, and Candida Biofilm Drug Resistance

  2026-09-04

  This 2025 study identifies the PP2A catalytic subunit PPH21 as a regulator of Candida albicans biofilm formation and antifungal resistance through Atg13 phosphorylation and Atg1-associated autophagy. Its combination of genetic, pharmacological, cellular, and mouse oral-infection experiments suggests that interrupting PP2A-dependent autophagy may improve treatment responses against resistant biofilms.

• SARS-CoV-2 NSP15 Inhibitors from Natural Products

  2026-09-04

  This 2021 structure-based study screened a natural-product library against the SARS-CoV-2 NSP15 endoribonuclease and prioritized thymopentin and oleuropein. Molecular-dynamics analysis supported stable protein–ligand complexes, but biochemical and cellular validation remained necessary before these computational hits could be considered antiviral inhibitors.

• Magnetic CAR-T Mimicry for Solid Tumors

  2026-09-03

  The reference study introduces M-BiNanoAb, a magnetic bispecific nano-antibody that recruits endogenous T cells, functionally redirects them toward PD-L1-positive tumor cells, and guides their tumor infiltration with an external magnetic field. This non-genetic, in vivo strategy addresses key barriers in solid-tumor CAR-T therapy, although its preclinical efficacy, dependence on PD-L1 expression, and need for localized magnetic guidance require careful interpretation.

• Cyclodextrin Magnetic Nano-Adsorbents for Uremic Toxins

  2026-09-03

  The reference study develops magnetic nanoparticles coated with α-, β-, or γ-cyclodextrin and evaluates how surface chemistry and incubation time affect uremic-toxin adsorption. Its central contribution is showing that adsorption in a multicomponent solution cannot be interpreted from metabolite concentration alone, supporting more deliberate designs for blood-contacting toxin-removal systems.

• Praeruptorin A: From Fe²⁺ Screening to Translation

  2026-09-02

  Praeruptorin A is an angular pyranocoumarin compound whose strongest translational story begins with iron-centered ferroptosis screening. This article connects DMT1, cardiomyopathy, intestinal inflammation, and metastasis findings to practical assay decisions and evidence boundaries.

• Multianimal MRI for Pancreatic Tumor Monitoring

  2026-09-02

  Kempinska and colleagues introduce a four-chamber MRI workflow that images up to four KPC mice in one acquisition, improving the efficiency of pancreatic tumor detection and longitudinal measurement. The study also demonstrates how standardized MRI endpoints can support a gemcitabine treatment-response experiment without sacrificing anatomical detail.

• Gemcitabine HCl: From Assay Signal to MRI

  2026-09-01

  Gemcitabine HCl research is most informative when molecular cytotoxicity measurements are interpreted alongside longitudinal tumor anatomy. This guide presents a decision-focused framework for connecting DNA replication inhibition, apoptosis assays, and multianimal MRI without treating any single endpoint as a complete measure of therapeutic response.

• SMC2 and SMC4 in Breast Cancer Prognosis

  2026-09-01

  The 2024 study integrated multi-database bioinformatics with cell and xenograft experiments to identify SMC2 and SMC4 as independent prognostic factors in breast cancer. Its drug-response findings further suggest that SMC2/SMC4 status may influence sensitivity to 5-Fluorouracil and oxaliplatin, although prospective and subtype-specific validation remains necessary.

• Cimetidine for BBB and Cancer Research Workflows

  2026-08-31

  Cimetidine can serve as a mechanistic H2R probe across barrier-transport and gastrointestinal cancer workflows without being mistaken for a validated BBB standard. This guide combines practical Transwell assay design, lysosomal-trapping controls, solubility handling, and interpretation strategies for more reproducible research.

• Talabostat Mesylate: Reframing FAP and DPP4 Biology

  2026-08-31

  Talabostat mesylate, also known as PT-100 or Val-boroPro, offers translational researchers a way to interrogate the intersection of DPP4 biology, FAP-positive stroma, immune signaling, and hematopoiesis. This article connects enzymatic mechanism with experimental strategy, biomarker development, and the practical limits of interpreting antitumor activity.

• Oligo (dT) 25 Beads: Practical mRNA Workflow

  2026-08-30

  Oligo (dT) 25 Beads provide a magnetic method for enriching polyadenylated eukaryotic mRNA from total RNA or eukaryotic cell and tissue samples. They are appropriate for mRNA-focused workflows such as RT-PCR and cDNA synthesis, but should not be treated as a universal method for non-polyadenylated RNA, prokaryotic RNA, or unbiased total-RNA recovery.

• SmD2 Acetylation Shapes PARP Response in HCC

  2026-08-29

  This 2024 Nature Communications study identifies acetylation-dependent control of the spliceosome protein SmD2 as a mechanistic link between alternative splicing, BRCA1/FANC expression, DNA damage repair, and PARP inhibitor sensitivity in hepatocellular carcinoma. Its preclinical data support SmD2 and the HDAC2–p300 regulatory axis as potential determinants of response, while combination treatment with Romidepsin and Olaparib provides a rationale for further investigation in BRCA-proficient HCC.

• Plk1 Control of p31comet in Mitotic Checkpoint Exit

  2026-08-28

  The reference study identifies Polo-like kinase 1 (Plk1) as a direct regulator of p31comet, showing that phosphorylation at S102 suppresses p31comet–TRIP13-mediated disassembly of mitotic checkpoint complexes. This mechanism helps explain how active checkpoint signaling avoids a futile cycle of MCC assembly and disassembly and provides a useful framework for studying mitotic exit control.

• Genomic Instability and Therapy Heterogeneity in CRC

  2026-08-28

  Cho et al. combine patient-derived xenografts with whole-exome, transcriptomic, and DNA-methylation profiling to show that colorectal cancer metastasis is accompanied by coordinated genomic and regulatory change. Their results connect metastatic evolution with heterogeneous treatment responses, providing a mechanistic framework for studying resistance beyond a static primary-tumor biopsy.

• U 46619: From TP Signaling to Translational Strategy

  2026-08-27

  U 46619, also known as 11,9 epoxymethano-prostaglandin H2, is a selective TP receptor agonist that connects platelet activation with vascular and renal research. This thought-leadership guide shows how to use its mechanism, concentration-dependent readouts, and translational limitations to design stronger platelet, vascular tone, and hypertension studies.

8121 records 1/542 page Next 12345 下5页 Last page